Monopar Therapeutics Inc. (MNPR) Revenue and Competitors
Estimated Revenue & Valuation
- Monopar Therapeutics Inc. (MNPR)'s estimated annual revenue is currently $3.1M per year.
- Monopar Therapeutics Inc. (MNPR)'s estimated revenue per employee is $155,000
Employee Data
- Monopar Therapeutics Inc. (MNPR) has 20 Employees.
- Monopar Therapeutics Inc. (MNPR) grew their employee count by -9% last year.
Monopar Therapeutics Inc. (MNPR)'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder and Executive Chairman | Reveal Email/Phone |
2 | Co-Founder and EVP, Research and Development Chief Scientific Officer | Reveal Email/Phone |
3 | Director, Clinical Operations | Reveal Email/Phone |
4 | Director Clinical Strategy and Development | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Associate Director, Finance and Administration | Reveal Email/Phone |
7 | Senior Clinical Research Associate | Reveal Email/Phone |
8 | Accounting Associate | Reveal Email/Phone |
9 | CEO/Co-Founder | Reveal Email/Phone |
10 | Senior Scientist | Reveal Email/Phone |
Monopar Therapeutics Inc. (MNPR) Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.8M | 18 | -14% | N/A | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $707.3M | 2852 | 14% | $1.1B | N/A |
#5 | $1.7M | 11 | 0% | N/A | N/A |
#6 | $32.6M | 210 | 6% | N/A | N/A |
#7 | $2.6M | 17 | 6% | N/A | N/A |
#8 | $1.1M | 7 | -30% | N/A | N/A |
#9 | $1.4M | 9 | -10% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Monopar Therapeutics Inc. (MNPR)?
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.
keywords:N/A
N/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Monopar Therapeutics Inc. (MNPR) News
Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Growth in Short Interest. Posted by admin on Apr 16th, 2022. Share on Twitter Share on Facebook Share on...
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Rating) saw a significant decline in short interest in the month of March. As of March 15th,...
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical...
Other Companies in Wilmette
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.7M | 25 | -39% | N/A |
#2 | $3.2M | 33 | 3% | N/A |
#3 | $7.3M | 34 | 10% | N/A |
#4 | $4.3M | 36 | 0% | N/A |
#5 | N/A | 38 | -3% | N/A |